0001072588-14-000131.txt : 20141212
0001072588-14-000131.hdr.sgml : 20141212
20141212130508
ACCESSION NUMBER: 0001072588-14-000131
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 3
CONFORMED PERIOD OF REPORT: 20141201
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20141212
DATE AS OF CHANGE: 20141212
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CANNAPHARMARX, INC.
CENTRAL INDEX KEY: 0001081938
STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770]
IRS NUMBER: 274635140
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-27055
FILM NUMBER: 141282923
BUSINESS ADDRESS:
STREET 1: ONE COLLINS DRIVE
CITY: CARNEYS POINT
STATE: NJ
ZIP: 08069
BUSINESS PHONE: 720-939-1133
MAIL ADDRESS:
STREET 1: ONE COLLINS DRIVE
CITY: CARNEYS POINT
STATE: NJ
ZIP: 08069
FORMER COMPANY:
FORMER CONFORMED NAME: GOLDEN DRAGON HOLDING CO.
DATE OF NAME CHANGE: 20110125
FORMER COMPANY:
FORMER CONFORMED NAME: CCVG, INC.
DATE OF NAME CHANGE: 20101117
FORMER COMPANY:
FORMER CONFORMED NAME: CONCORD VENTURES, INC.
DATE OF NAME CHANGE: 20071003
8-K
1
gdhc8kpressreleases.txt
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 1, 2014
CANNAPHARMARX, INC.
---------------------
(Exact name of Registrant as specified in its charter)
Delaware 000-27055 24-4635140
---------------------------- -------------------------- ---------------------
(State or other jurisdiction (Commission File Number) (IRS Employer Identi-
of incorporation) fication No.)
One Collins Drive, Salem Business Center, Carneys Point, NJ 08069-3640
--------------------------------------------------
(Address of principal executive offices)
720-939-1133
-----------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
-----------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
SECTION 7 - REGULATION FD
Item 7.01 Regulation FD Disclosure
Press Release on December 1, 2014
---------------------------------
The information in this Item 7.01 of this Current Report is furnished pursuant
to Item 7.01 and shall not be deemed "filed" for any purpose, including for the
purposes of Section 18 of the Exchange Act, or otherwise subject to the
liabilities of that Section. The information in this Current Report on Form 8-K
shall not be deemed incorporated by reference into any filing under the
Securities Act or the Exchange Act regardless of any general incorporation
language in such filing.
On December 1, 2014, CannaPharmaRx, Inc. made a press release announcing its new
headquarters. The text of the press release is attached hereto as Exhibit 99.1.
Press Release on December 4, 2014
---------------------------------
On December 4, 2014, CannaPharmaRx, Inc. made a press release announcing its new
financial controller. The text of the press release is attached hereto as
Exhibit 99.2.
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits
The following is a complete list of exhibits filed as part of this
Report. Exhibit numbers correspond to the numbers in the exhibit table of Item
601 of Regulation S-K.
Exhibit # Description
99.1 Press Release dated December 1, 2014
99.2 Press Release dated December 4, 2014
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CANNAPHARMRARX, INC.
By: /s/ Gerry Crocker
-----------------------------------------
Gerry Crocker
Chief Executive Officer
Date: December 11, 2014
EX-99
2
ex99-1.txt
EXHIBIT 99.1
CannaPharmaRx, Inc. Officially Opens
Headquarters in New Jersey
December 1, 2014: CannaPharmaRx, Inc., (OTC: GDHC), the New Jersey-based
pharmaceutical research and discovery company, officially took possession of its
new headquarters in Carney's Point Township in southwest New Jersey - a state
that is home to 14 of the 20 largest pharmaceutical companies in the world.
"Establishing our headquarters in New Jersey puts us in close proximity to some
of the most experienced pharmaceutical executives in the world." said Gerry
Crocker, CannaPharmaRx CEO. "Not only is it a rich source of human capital, it
is ideally geographically positioned for easy access to our staff and
development partners."
Pharmaceutical companies located in New Jersey include Johnson & Johnson,
Bristol-Myers Squibb, Merck & Co. and Novo Nordisk. Further, an estimated 22,000
students in New Jersey graduate each year with degrees in the life sciences from
New Jersey's colleges and universities.1 The state also boasts that its heavy
concentration of medical institutions and population density provides an
environment conducive to clinical trials.
The pharmaceutical industry in New Jersey benefits from its location, which is
within easy reach of major cities including New York, Philadelphia and
Baltimore. CannaPharmaRx's offices are in close proximity to Philadelphia
airport, Wilmington and Philadelphia train stations and the I-95 and New Jersey
Turnpike corridor.
CannaPharmaRx expects to derive value from various New Jersey tax incentives
provided to pharmaceutical companies who establish residence in the state.
About CannaPharmaRx: Headquartered in Carney's Point, New Jersey, CannaPharmaRx
is a pharmaceutical company whose mission is to advance cannabinoid discovery,
science, research & development, and to bring novel prescription, veterinary and
personal care cannabinoid-based products to market in the U.S. and worldwide.
For more information, visit www.cannapharmarx.com.
Forward Looking Statements: Certain statements in this press release are
forward-looking within the meaning of the Private Securities Litigation Reform
Act of 1995. These statements may be identified by the use of forward-looking
words such as "anticipate," "believe," "forecast," "estimated" and "intend,"
among others. These forward-looking statements are based on CannaPharmaRx's
current expectations and actual results could differ materially. There are a
number of factors that could cause actual events to differ materially from those
indicated by such forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a going concern;
our need for additional financing; uncertainties of patent protection and
litigation; clinical trials involve a lengthy and expensive process with an
uncertain outcome, and results of earlier studies and trials may not be
predictive of future trial results; uncertainties of government or fourth party
payer reimbursement; limited sales and marketing efforts and dependence upon
fourth parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any pharmaceutical
products under development, there are significant risks in the development,
regulatory approval and commercialization of new products. There are no
guarantees that future clinical trials discussed in this press release will be
completed or successful or that any product will receive regulatory approval for
any indication or prove to be commercially successful. CannaPharmaRx does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in CannaPharmaRx's private
placement agreement and Form 10-Q as of September 30, 2014 (Unaudited) and other
periodic reports filed with the Securities and Exchange Commission.
SOURCE: CannaPharmaRx, Inc.
Contacts:
Ari Herrera, Interlinked, ari@interlinked.com
Delray Wannamaker, Interlinked, delray@interlinked.com
Kathleen Wolff, CannaPharmaRx, kwolff@cannapharmarx.com
EX-99
3
ex99-2.txt
EXHIBIT 99.2
CannaPharmaRx, Inc. Announces New Financial Controller
to be based in NJ Headquarters
December 4, 2014: CannaPharmaRx, Inc., (OTCQB: GDHC), the New Jersey-based
pharmaceutical research and discovery company, today announced the hiring of
Thomas J. Della-Franco III as Financial Controller. Mr. Della-Franco will work
on a consulting basis out of the company's new headquarters in Carney's Point,
New Jersey.
"Tom's diverse work experience is an excellent fit for our rapidly evolving
company. He is a highly accomplished financial executive with expertise in
manufacturing, importing and distribution, and with demonstrated success in
financing, refinancing, restructurings and mergers & acquisitions," said Gerry
Crocker, CEO, CannaPharmaRx.
In his most recent position as Chief Financial Officer for ZPC Holdings, Mr.
Della-Franco led the company's Sarbanes Oxley (SOX) compliance, strategic
acquisitions, LBOs, private equity rounds and was the key contact for due
diligence rounds prior to the company's sale to a Fortune 500 company. Prior to
ZPC Holdings, Mr. Della-Franco worked as Senior Auditor for the auditing firm of
Peat, Marwick Mitchell & Company (now KPMG) in Philadelphia.
"For me, the most rewarding position is one where I can have a balance of
strategic and hands-on financial management. At CannaPharmaRx, I am looking
forward to helping to identify and capture opportunities to help the company
accelerate, expand and grow," said Mr. Della-Franco.
This week, CannaPharmaRx officially announced the opening of its New Jersey
headquarters where its administrative offices, including finance, are now based.
Financial information can be found in the company's form 10-Q filing for the
fiscal third quarter ending September 30 which was filed with the Securities and
Exchange Commission on November 19.
About CannaPharmaRx: Headquartered in Carney's Point, New Jersey, CannaPharmaRx
is a pharmaceutical company whose mission is to advance cannabinoid discovery,
science, research & development, and to bring novel prescription, veterinary and
personal care cannabinoid-based products to market in the U.S. and worldwide.
For more information, visit www.cannapharmarx.com.
Forward Looking Statements: Certain statements in this press release are
forward-looking within the meaning of the Private Securities Litigation Reform
Act of 1995. These statements may be identified by the use of forward-looking
words such as "anticipate," "believe," "forecast," "estimated" and "intend,"
among others. These forward-looking statements are based on CannaPharmaRx's
current expectations and actual results could differ materially. There are a
number of factors that could cause actual events to differ materially from those
indicated by such forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a going concern;
our need for additional financing; uncertainties of patent protection and
litigation; clinical trials involve a lengthy and expensive process with an
uncertain outcome, and results of earlier studies and trials may not be
predictive of future trial results; uncertainties of government or fourth party
payer reimbursement; limited sales and marketing efforts and dependence upon
fourth parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any pharmaceutical
products under development, there are significant risks in the development,
regulatory approval and commercialization of new products. There are no
guarantees that future clinical trials discussed in this press release will be
completed or successful or that any product will receive regulatory approval for
any indication or prove to be commercially successful.
CannaPharmaRx does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors set forth in
CannaPharmaRx's private placement agreement and Form 10-Q as of September 30,
2014 (Unaudited) and other periodic reports filed with the Securities and
Exchange Commission.
SOURCE: CannaPharmaRx, Inc.
Contact: Kathleen Wolff, CannaPharmaRx, kwolff@cannapharmarx.com